Regulatory FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy Pharmaceutical TechnologyAstraZeneca has secured FDA approval for Imfinzi in combination with BCG induction and maintenance therapy for adults with BCG-nave, high-risk NMIBC.OncologyRead full story pharminent June 1, 2026 (Last updated: June 1, 2026) Pharmaceutical Technology AstraZeneca has secured FDA approval for Imfinzi in combination with BCG induction and maintenance therapy for adults with BCG-nave, high-risk NMIBC. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Previous PostNext: Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
